Bayer AG is positioning its pharmaceuticals division for a comeback, with a focus on new treatments for cancer and kidney disease. The German conglomerate aims to counterbalance the revenue hit from patent expirations with these promising therapies. This strategy is part of a broader effort by Bayer to diversify and strengthen its pharma arm, which has faced challenges in recent years due to the loss of exclusivity for key products.

By investing in innovative treatments, Bayer hopes to re-establish itself as a leader in the pharmaceutical sector. The company's leadership is confident that these new drugs will drive growth, despite a competitive market and the ongoing pressure of healthcare cost containment. As Bayer pivots towards these new therapeutic areas, it signals a shift from its historical focus on cardiovascular and women's health products.

The success of these initiatives will be critical for Bayer's future, as the company seeks to maintain its relevance in a rapidly evolving pharmaceutical industry.